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Background: In previous studies, neurons were documented to undergo apoptosis in the presence of microglia
and live Borrelia burgdorferi, but not with either agent alone. Microscopy showed that several Toll-like receptors
(TLRs) were upregulated in microglia upon B. burgdorferi exposure. It was hypothesized that the inflammatory milieu
generated by microglia in the presence of B. burgdorferi results in neuronal apoptosis and that this inflammation
was likely generated through TLR pathways.
Methods: In this study, we explored the role of several TLR and nucleotide-binding oligomerization domain
containing 2 (NOD2)-dependent pathways in inducing inflammation in the presence of B. burgdorferi, using
ribonucleic acid interference (RNAi) and/or inhibitors, in primary non-human primate (NHP) microglia. We also
used several inhibitors for key mitogen-activated protein kinase (MAPK) pathways to determine the role of
downstream pathways in inflammatory mediator release.
Results: The results show that the TLR2 pathway plays a predominant role in inducing inflammation, as inhibition
of TLR2 with either small interfering RNA (siRNA) or inhibitor, in the presence of B. burgdorferi, significantly
downregulated interleukin 6 (IL-6), chemokine (C-X-C) motif ligand 8 (CXCL8), chemokine (C-C) motif ligand 2
(CCL2), and tumor necrosis factor (TNF) production. This was followed by TLR5, the silencing of which
significantly downregulated IL-6 and TNF. The role of TLR4 was inconclusive as a TLR4-specific inhibitor and
TLR4 siRNA had opposing effects in the presence of B. burgdorferi. Silencing of NOD2 by siRNA in the presence
of B. burgdorferi significantly upregulated IL-6, CCL2, and TNF. Downstream signaling involved the adaptor
molecule myeloid differentiation primary response 88 (MyD88), as expected, as well as the MAPK pathways,
with extracellular signal-regulated kinase (ERK) being predominant, followed by Jun N-terminal kinase (JNK)
and p38 pathways.
Conclusions: Several receptors and pathways, with both positive and negative effects, mediate inflammation
of primary microglia in response to B. burgdorferi, resulting in a complex, tightly regulated immune network.
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Lyme disease, caused by the spirochete Borrelia burgdorferi,
is the leading cause of vector-borne illness in the
northern hemisphere, including in the United States
[1,2]. Transmitted through the bite of an infected tick,
the bacteria disseminates to distal areas, resulting in
carditis, uveitis, arthritis, and/or neuroborreliosis of the
central and/or peripheral nervous systems (CNS, PNS)
[3-6]. Lyme neuroborreliosis, or LNB, is the most morbid
form of Lyme disease, due to its at times debilitating and
long-lasting neurological sequelae. Signs and symptoms of
CNS/PNS disease include meningitis, cranial neuritis,
encephalopathies, and encephalomyelitis (rarely), as well
as radiculoneuropathy and limb pain or sensory loss [7].
While the type of neurological manifestation varies be-
tween patients, a common occurrence is the presence of
inflammation, both in LNB as well as in other forms of
Lyme disease. The presence of cerebrospinal fluid pleocy-
tosis and perivascular cell infiltrates local to peripheral
nerves, brain, and meninges, and other tissues have been
recorded in animal models of Lyme disease as well as in
human patients [8-10]. Such responses are often accompan-
ied by the production of inflammatory mediators such as
interleukin 1-beta (IL-1β), interleukin 6 (IL-6), interferon-
gamma (IFNγ), tumor necrosis factor (TNF), chemo-
kine (C-C) motif ligand 2 (CCL2), chemokine (C-X-C)
motif ligand 8 (CXCL8), and several others, secreted
both by resident cells as well as incoming cells of the
immune system [11-15]. Manifestation of such reactive
inflammation has often been shown to play a key role
in several CNS pathologies such as CNS injury and neuro-
degenerative diseases [16-19]. By analogy, we hypothesized
that such an inflammatory process in the CNS as caused
by B. burgdorferi plays a role in neuronal and/or glial cell
dysfunction, leading to cell loss through apoptosis, and
would underlie the pathogenesis of LNB. In evidence, sev-
eral studies from our laboratory have shown that exposure
of brain cells, sections, or tissues to B. burgdorferi, be it
ex vivo, in vivo, or in vitro, results in production of inflam-
matory mediators such as IL-6, CCL2, CXCL8, and others
and is often accompanied by apoptosis of neurons or oli-
godendrocytes [20-22]. In vitro studies have shown that
neuronal loss can occur in the presence of B. burgdorferi
and microglia, a leading contributor of inflammatory me-
diators in the CNS, while oligodendrocytes were suscep-
tible to B. burgdorferi alone and required no other cell
involvement to undergo apoptosis [20,23]. However, as
with neurons, oligodendrocyte cell loss occurred within an
inflammatory milieu. Furthermore, application of an anti-
inflammatory drug mitigated this effect in vitro in oligoden-
drocytes [20], confirming our hypothesis that inflammation
contributes to CNS pathology due to B. burgdorferi.
Currently, several studies are being undertaken in our
laboratory to delineate the molecular mechanisms leadingto inflammatory mediator release from the resident cells
of the CNS when exposed to B. burgdorferi. The hypoth-
esis is that determination of inflammatory mechanisms
will also lead to elucidation of cell death mechanisms and
thereby provide additional targets of intervention. In a re-
cent study, we have shown that the mitogen-activated
protein kinase (MAPK) pathways, particularly the
MAP kinase kinase (MEK)/extracellular signal-regulated
kinase (ERK) pathway, play a prominent role in the pro-
duction of inflammatory mediators from oligodendrocytes
as well as apoptosis of these cells [24]. In a previous study,
a role for Toll-like receptors was indicated when suppres-
sion of the TLR2 mRNA through small interfering RNA
(siRNA) technology reduced inflammatory mediator pro-
duction in THP1 monocytes in response to B. burgdorferi
[25]. Upregulation of TLR2, TLR4, and TLR5 receptors
was also seen in primary microglia upon exposure to the
bacteria [26]. In this current study, we expand this obser-
vation by delineating a role for such receptors as well as
nucleotide-binding oligomerization domain containing 2
(NOD2), and for associated MAPK pathways in chemo-
kine and cytokine production by primary non-human pri-
mate microglia, in response to B. burgdorferi. We show
using an additional set of animals to those used in prior
publications that the net production of inflammatory me-
diators is through positive and negative regulation by mul-
tiple microglial receptors and pathways.
Methods
Bacterial strain and culture
B. burgdorferi strain B31 (clone 5A19) was used through-
out the course of this study. The strain was routinely
cultured in Barbour-Stoenner-Kelly (BSK-H) medium
(Sigma-Aldrich, St. Louis, MO) with 0.25 μg/mL ampho-
tericin, 193 μg/mL phosphomycin, and 45.4 μg/mL rifam-
picin for about 5 to 6 days under microaerophilic
conditions. Bacterial concentration was determined using
a dark field microscope, and the required number of bac-
teria was harvested by centrifugation at 2,095 × g for
30 min at room temperature, without brakes. The result-
ing bacterial pellet was resuspended in DMEM:F12
(Invitrogen/Life Technologies, Inc., Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS) to
the same concentration prior to pelleting and diluted
further to the required multiplicity of infection (MOI).
Isolation and culture of primary microglia
Microglial cells were isolated from frontal cortex tissues
of rhesus macaque (Macaca mulatta) brains according
to previously published protocols [23]. The tissues were
obtained from uninfected animals from the breeding
colony that were euthanized due to persistent diarrhea
or injury. Euthanasia was performed according to the proto-
cols recommended and approved by the Tulane Institutional
Parthasarathy and Philipp Journal of Neuroinflammation  (2015) 12:60 Page 3 of 14Animal Care and Use Committee. The microglial isolation
protocol was as follows. The leptomeninges and leptomen-
ingeal blood vessels were removed first, followed by
mechanical mincing of the cortex tissue with scalpels.
The minced tissue was enzymatically digested with
0.25% Trypsin-EDTA containing 200 Kunitz unit/mL
DNaseI (Sigma-Aldrich, St. Louis, MO) at 37°C for
20 min with occasional shaking. This enzymatically disso-
ciated tissue was then centrifuged (335 × g, 10 min), and
the upper layer of cells was removed and filtered through
a 20- to 30-μm Nitex filter. The filtrate was resuspended
in DMEM:F12 supplemented with 10% FBS, 1% penicillin-
streptomycin, and 0.5 ng/mL granulocyte-macrophage
colony-stimulating factor (GM-CSF) and seeded as aggre-
gate cultures in T-75 flasks, with the medium changed
every 4 days for about 4 weeks. Microglial cells were dis-
lodged from the aggregate cultures by vigorous tapping on
the sides of the culture flasks, collected and seeded at the
required density. All assays were conducted within 2 to
3 days after seeding of cells. The purity of the microglial
culture was determined by staining with antibody to
the Iba1 phenotypic marker (Wako Chemicals USA,
Richmond, VA) and was assessed to be between 92%
and 95%. A total of nine animals were used in this study.
Infection assays with receptor/pathway inhibitors
Assays were carried out with approximately 1 to 2 × 104
cells/well of microglia seeded in 24-well tissue culture
plates. At the time of the assay, the culture medium was
removed and replaced with fresh medium without anti-
biotics, and the cells were pretreated with the pertinent
inhibitors for 2 h prior to adding B. burgdorferi (MOI of
10:1). The microglial cells were incubated with the bac-
teria and inhibitors for a further 24 h, followed by col-
lection of supernatant after centrifuging at 2,095 × g for
10 min at 4°C. Supernatants were stored at −20°C until
analysis. The following inhibitors were used: SB203580
and BIRB796 (p38); U0126 (MEK1/2); SP600125 and Jun
N-terminal kinase (JNK) inhibitor VIII (JNK) (all but
one were from EMD Millipore, Billerica, MA; BIRB796
was obtained from Cayman Chemical Co., Ann Arbor, MI);
and oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphorylcholine (OxPAPC) (TLR2/4), CLI-095 (TLR4),
Gefitinib (RipK2), and myeloid differentiation primary
response 88 (MyD88) inhibitory peptide (InvivoGen,
San Diego, CA).
Pam3CSK4 (Imgenex, San Diego, CA), LPS O55:B5
(Sigma-Aldrich, St. Louis, MO), or muramyl dipeptide
(MDP, InvivoGen) were included as positive control ago-
nists when required.
RNAi
Gene silencing of specific receptors or adaptor mole-
cules was carried out using siRNA technology, accordingto Dennis et al. [25]. Briefly, approximately 2 × 104
microglia/well were seeded in 24-well plates for 48 h,
and culture medium replaced with 100 μL antibiotic-
free medium. Transfection complexes were generated
using 2 μL HiPerfect transfection reagent (Qiagen, Valencia,
CA) and 15 to 30 nM siRNA (Santa Cruz Biotechnology,
Dallas, TX) in antibiotic- and serum-free medium. The
complexes were incubated at room temperature for 30 min
and 100 μL of the complex was added to cells. After a 6-h
incubation at 37°C and 5% CO2, 400 μL of antibiotic-free
medium was added and further incubated for 18 h,
followed by addition of B. burgdorferi (MOI 10:1) or
receptor-specific positive controls. After a 24-h incu-
bation with bacteria or controls, supernatants were
collected as before and analyzed for chemokine and
cytokine expression. A non-specific control siRNA was
used as negative control for all experiments. In addition to
the positive controls mentioned previously, FliC (from
Salmonella typhimurium, Enzo Lifesciences, Farmingdale,
NY) was used as a TLR5-specific control when required.
To determine the efficacy of TLR2 and NOD2 siRNA,
4-well chamber slides were seeded as before and experi-
mentation was carried out as described previously, with
B. burgdorferi and MDP as treatment groups, respect-
ively. Processing of chamber slides for immunofluores-
cence was carried out according to previously published
protocols [24]. Rabbit polyclonal primary antibody
(1:40 titer) was used for identifying TLR2 (Santa Cruz
Biotechnology, Dallas, TX), while a mouse monoclonal
was used for NOD2 (1:50; Cayman Chemical Co., Ann
Arbor, MI). Appropriate secondary antibodies conjugated
to Alexa 488 (1:800 titer) were used to visualize the recep-
tors through fluorescent microscopy.
Microscopy
Receptor-positive cells were visualized using a Leica
DMRE fluorescent microscope (Leica microsystems,
Buffalo Grove, IL) and Lumencor SOLA GUI software
(Lumencor, Beaverton, OR). Percentage of cells posi-
tive for receptors in each treatment group was calculated
and graphed using Microsoft Excel®. Approximately 15 to
20 fields were counted for each chamber, and when re-
quired, cells were imaged using Nuance Multispectral
Imaging System (CRi, PerkinElmer, Waltham, MA).
Adobe® Photoshop CS6 software was used to assemble
the images.
Cytotoxicity assay
The cytotoxicity of various concentrations of siRNA and
inhibitors on microglia was assayed using tetrazolium
dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) as a substrate and conducted accord-
ing to the manufacturer’s protocols (Sigma-Aldrich, St.
Louis, MO). Briefly, 5 mg/mL MTT was added to cells
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MTT added corresponded to 10% of the volume of the
medium in the wells. After 2 h, the cells were solubi-
lized using the solubilization solution provided and the
resulting colored solution was read at 570 nm. The results
were normalized to cells treated with either control siRNA
or cells with no inhibitors.
Quantitation of chemokines and cytokines
Enzyme-linked immuno-sorbent assays (ELISAs) for IL-6,
CXCL8, CCL2, and TNF were carried out using custom
non-human primate-Multiplex kits from EMD Millipore
(Billerica, MA) at the Pathogen Detection and Quantification
Core, Tulane National Primate Research Center, and
performed according to the manufacturer’s protocols.
An additional 27-plex human chemokine/cytokine kit
(BioRad, Hercules, CA) was used for exploratory ex-
periments or to obtain preliminary data. The results
were graphed using Microsoft Excel® and figures were
assembled using Microsoft Powerpoint® and Adobe®
Photoshop CS6.
Statistics
Statistical significance was determined using Student’s
t-test, with values being in duplicate for each analysis.
The results were considered significantly different if
the probability values (P) were <0.05.
Results
Role of microglial Toll-like receptors and adaptor molecules
in B. burgdorferi-induced inflammation
In previous studies, a role for Toll-like receptors (TLRs),
particularly TLR2, 4, and 5, in mediating inflammation
in microglia in response to B. burgdorferi was indicated
by the upregulation of these receptor proteins, as evi-
denced through confocal microscopy [26]. In the present
study, a more direct evidence for such a role was sought
with the help of TLR-specific siRNA and/or inhibitors,
when these were available. siRNA was used at a concen-
tration of 25 nM unless otherwise stated. The toxicity of
transcription complexes at higher concentrations (>50
nM) was tested with an MTT-based assay and varied be-
tween animals. Hence, these data are not shown here.
Lower concentrations of siRNA (e.g., 25 nM) were also
tested for toxicity by the MTT-based assay and were
deemed non-toxic.
TLR2 emerged as a prominent receptor in inducing
inflammation from primary microglia in response to
B. burgdorferi exposure (Figures 1 and 2). Suppression of
TLR2 mRNA through ribonucleic acid interference (RNAi)
as well as inhibition of TLR2/4 signaling by OxPAPC
(10 μg/mL) in the presence of B. burgdorferi significantly
downregulated the release of all four inflammatory media-
tors tested. OxPAPC did not affect the viability of thebacteria and was non-toxic to microglia at this concentra-
tion (data not shown). The efficacy of siRNA or the inhibi-
tor was determined through TLR2- and TLR4-specific
ligands Pam3CSK4 and LPS, respectively. As seen in
Figures 1 and 2, both positive controls worked as expected,
indicating that the specificity of the siRNA/inhibitor was
on target. However, considering that the suppression of
chemokines/cytokines was more effective when stimulating
with LPS than with Pam3CSK4, it is likely that the inhibitor
is more effective for TLR4 than TLR2, although it does
affect both signaling pathways [27]. In addition, the efficacy
of TLR2 siRNA was confirmed using immunofluorescence
and microscopy, as well. The overall stimulation of TLR2
in the glial cells was low, with only approximately 25%
of cells being positive for the receptor in the presence
of B. burgdorferi, similar to previously published results
where up to a 10% stimulation has been observed [26]. In
the presence of B. burgdorferi, TLR2 siRNA (25 nM) sup-
pressed the percentage of TLR2 positive cells by about
20%, in comparison to cells that received the non-specific
control siRNA (data not shown), indicating that, albeit at
a low level, RNAi was achieved.
In order to evaluate more precisely if TLR4 played a
role in microglial stimulation with B. burgdorferi, a
TLR4-specific inhibitor, CLI-095, as well as a TLR4
siRNA was used. The inhibitor blocks signaling from the
intracellular domain of TLR4 rather than any adaptor
molecule associated with TLR4 and has been shown to
be specific for this receptor [28]. In contrast to OxPAPC,
which inhibits signaling at the extracellular level of
TLR2 and TLR4 (by competitive interaction with TLR2/
4 accessory proteins such as CD14, LBP, and MD2),
inhibition of intracellular TLR4 signaling significantly
increased the production of CCL2 (Table 1). The pro-
duction of IL-6 and CXCL8 also showed an increas-
ing trend when CLI-095 was used in the presence of
B. burgdorferi although not statistically significant in
a majority of experiments. The inhibitor also had no
significant effect on TNF secretion from microglia
with B. burgdorferi. Higher concentrations of CLI-095 were
toxic to cells and hence were not tested. Use of TLR4
siRNA (25 to 30 nM) in the presence of B. burgdorferi pro-
duced opposing results to the inhibitor data. Here, the
siRNA was effective in suppressing expression of CXCL8
significantly, while it showed a similar suppressing effect
for IL-6 and CCL2 production, an opposing trend to that
seen with CLI-095. The siRNA effect on TNF was an in-
creasing trend overall, although again not significant, and
again opposite to the data with CLI-095. In contrast to the
results with B. burgdorferi, both the inhibitor and TLR4
siRNA significantly suppressed the production of IL-6,
CXCL8, and TNF in the presence of LPS with no effect on
CCL2. If the siRNA effects hold true, then TLR4 contrib-
utes only towards CXCL8 production, but if the inhibitor
Figure 1 Role of microglial TLR2 receptor in mediating innate immune responses to B. burgdorferi. Primary microglia were incubated with
25 nM TLR2 or a non-specific control (CTL) siRNA (described in the ‘Methods’ section) followed by infection with B. burgdorferi for 24 h. Supernatants
were collected at 24 h post addition of the spirochetes and assayed for cytokine and chemokine levels by a multiplex ELISA. Data are representative of
three experiments using microglia from two animals. Pam3CSK4 was used as a positive control and cell culture medium as the negative control. Bars
represent standard deviation. *P < 0.05; **P < 0.01; ***P < 0.001. CCL2, chemokine (C-C) motif ligand 2; CXCL8, chemokine (C-X-C) motif ligand 8; IL-6,
interleukin 6; siRNA, small interfering RNA; TLR, Toll-like receptor; TNF, tumor necrosis factor.
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In either case, in light of these results, it is likely that the
predominant effect of OxPAPC on microglia in the pres-
ence of B. burgdorferi (Figure 2) was delivered via
TLR2 rather than through TLR4.
As with TLR2, silencing of microglial TLR5 mRNA
also suppressed cytokine expression but had no effect on
the expression of chemokines by these cells, when
siRNA was used at a similar concentration in the pres-
ence of the bacteria (Figure 3). In the presence of the
positive control FliC; however, TLR5 siRNA did suppress
the production of all four mediators tested, indicating
that this effect was specific for B. burgdorferi and again
not due to siRNA defects. There was a small but statisti-
cally significant increase in CXCL8 production in the
presence of TLR5 siRNA in medium controls. As the tis-
sue culture medium contained serum, which is a complex
mix of proteins and other biomolecules, it is conceivable
that this small effect was induced through serum compo-
nents. A similar explanation could also hold true for thelow levels of chemokine expression seen with medium-
only controls in Figure 1. Since microglia was isolated
from animals with injury or persistent diarrhea, medium
controls without additional stimulation were included in
all experiments to detect baseline inflammatory mediator
production. As seen in Figures 1, 2, and 3, regardless of
the reason for euthanasia, baseline levels of chemokines
and cytokines in microglia were either very low (likely due
to serum components) or undetectable.
As most TLRs signal through the MyD88 adaptor mol-
ecule, we next determined the role of this molecule
through the use of specific peptide inhibitors and siRNA.
However, at low concentrations (≤10 μM), the inhibitor
had no conclusive effect while at higher concentrations
it was toxic to cells. Hence, further determinations were
carried out with siRNA alone. Suppression of MyD88
expression with specific siRNA significantly inhibited the
effect of B. burgdorferi on the production of all four me-
diators tested (Figure 4). This also occurred when the
stimulant was the TLR2 agonist Pam3CSK4. However,
Figure 2 Effect of a TLR2/4 inhibitor on inflammation induced by B. burgdorferi in microglia. Primary microglia were pretreated with
10 μg/mL OxPAPC, a TLR2/4 inhibitor, for 2 h, followed by B. burgdorferi for an additional 24 h. The inhibitor was co-incubated with the bacterium
for the duration of infection. After 24 h, the supernatants were collected and stored until analysis. Data are representative of three independent
experiments with microglia cultured from two animals. LPS and Pam3CSK4 are positive controls for the inhibitor with the medium serving as
control for baseline expression. Bars represent standard deviation. *P < 0.05; **P < 0.01; ***P < 0.001. CCL2, chemokine (C-C) motif ligand 2;
CXCL8, chemokine (C-X-C) motif ligand 8; IL-6, interleukin 6; LPS, lipopolysaccharide; OxPAPC,
oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine.
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production in response to either B. burgdorferi or
Pam3CSK4, indicating that other adaptor molecules
might also play a role, in addition to possible siRNA
insufficiency.
NHP microglial NOD2 receptor plays an anti-inflammatory
role in B. burgdorferi-mediated inflammatory molecule
release
NOD2, an intracellular receptor that recognizes muramyl
dipeptide (MDP), has been shown to play a role in inflam-
matory responses to pathogens such as B. burgdorferi in
mouse astrocytes, mouse microglia, and human peripheral
blood mononuclear cells (PBMCs) [29-32]. We sought to
determine the role of the non-human primate microglial
NOD2 receptor in mediating inflammation that was trig-
gered by exposure to B. burgdorferi. MDP was used as a
positive control for NOD2 signaling. As seen in Figure 5,
suppression of NOD2 mRNA with siRNA (15 nM) in thepresence of B. burgdorferi resulted in a significantly higher
production of chemokines and cytokines with the excep-
tion of CXCL8, which remained unaffected. Higher con-
centrations of siRNA (25 to 30 nM) also showed a similar,
significant increase in the production of IL-6, CCL2, and
TNF, while it significantly downregulated CXCL8 (Table 2).
Silencing of NOD2 expression also generally enhanced the
production of pro-inflammatory mediators when the cells
were stimulated with MDP (Figure 5 and Table 2), indicat-
ing that the NOD2 pathway might be anti-inflammatory
in non-human primate (NHP) microglia and might be ac-
tivated to dampen an otherwise overwhelming immune
response that is taking place through other receptors.
We tried to confirm these data through use of the
receptor-interacting protein 2 (RIP2) tyrosine kinase
inhibitor Iressa (Gefitinib, 100 nM). However, Gefitinib,
which also inhibits epidermal growth factor receptor
(EGFR), had no conclusive effect when used in con-
junction with B. burgdorferi, but did upregulate CCL2
Table 1 Average fold changea in chemokine/cytokine
expression in the presence of various TLR4 inhibitors
Cytokine or chemokine/
treatment
IL-6 CXCL8 CCL2 TNF
Bb/CLI-095 0.901 0.977 0.884c 2.239
(±0.112) (±0.064) (±0.114) (±1.518)
LPS/CLI-095 1.705b 1.210b 0.957 2.330b
(±0.248) (±0.075) (±0.061) (±1.178)
Bb/TLR4 siRNA 1.218 1.261b 1.166 0.893
(±0.109) (±0.114) (±0.104) (±0.463)
LPS/TLR4 siRNA 1.905b 1.341b 1.075 3.720b
(±0.305) (±0.081) (±0.056) (±1.309)
aFold change values were calculated as B. burgdorferi or LPS with solvent
alone/B. burgdorferi or LPS with 0.5 μg/mL CLI-095 from five experiments for
each treatment with microglia from four animals. Similarly, fold change values
were calculated as treatments with control siRNA/treatments with 25 to 30 nM
TLR4 siRNA, from four experiments from four animals. Values higher than 1.0
represent fold-down regulation of chemokine/cytokine while values less than
1.0 represent an increase. Standard error of the mean (SEM) is indicated within
parentheses. bValues that were significantly downregulated in the majority of
experiments (≥60%). cA statistically significant increase in expression in those
experiments. Bb, B. burgdorferi; CCL2, chemokine (C-C) motif ligand 2; CXCL8,
chemokine (C-X-C) motif ligand 8; IL-6, interleukin 6; LPS, lipopolysaccharide;
siRNA, small interfering RNA; TLR, Toll-like receptor; TNF, tumor necrosis factor.
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from two animals (data not shown). Since NOD2 siRNA
showed a trend in increasing the production of inflamma-
tory mediators, with both the bacterium and the positive
control, we wanted to confirm the efficacy of this treat-
ment. In previous studies [26], it was shown that only
about 10% of microglia was activated in the presence of
B. burgdorferi, and therefore, even though TLR2 recep-
tors were seen to be upregulated microscopically, a
quantitative increase in receptor production could not
be proven by Western blot. Therefore, we decided to
test the efficacy of siRNA microscopically. As seen in
Figure 6, we also observed that an approximate 10% of
cells stained positive for NOD2 receptor in the pres-
ence of positive control MDP (Figure 6B), while it was
significantly downregulated in the presence of NOD2
siRNA, to about 5% of cells; a reduction of approxi-
mately 50%.
Microglial MAPK pathways are activated during B.
burgdorferi infection
Signaling through multiple receptors, including TLRs,
has been shown to activate MAPK and other pathways,
culminating in inflammatory mediator release. In previ-
ous studies that focused on oligodendrocytes, when cells
were exposed to B. burgdorferi, a predominant role for
the ERK pathway over other pathways was uncovered
[24]. In this study, since TLR pathways were shown to
be activated, we evaluated the role of individual MAPK
pathways in mediating inflammation due to B. burgdorferi.
As seen in Table 3, and as with oligodendrocytes, theMEK/ERK pathway, followed by JNK and p38 pathways,
played a predominant role in mediating chemokine/
cytokine release from primary microglia. At 2.5 μM in-
hibitor concentration, inhibition of the MEK/ERK path-
way suppressed production of all four mediators; this was
followed by JNK and p38 suppression, which inhibited the
production of four and three mediators each, respectively.
The p38 inhibitor had no conclusive effect on CCL2
release. Suppression of NFkB had no conclusive effects
in the two animals tested (data not shown). We also
tested two other inhibitors, BIRB 796 (p38) and JNK
inhibitor VIII, at the same concentration, and found that
the overall effect remained unchanged (data not shown).
Discussion
Toll-like receptors have been shown to play an import-
ant role in mediating inflammation in response to a
large variety of stimuli. The type and number of TLRs
involved depends both on the availability of specific
pathogen-associated molecular patterns (PAMP) of the
microbe in question, as well as host tissue-specific expres-
sion of TLRs, and may coordinate the overall immune re-
sponse towards that pathogen [33,34]. In previous studies,
we have shown via confocal microscopy that the TLR2, 4,
and 5 receptors were upregulated in NHP microglia in re-
sponse to B. burgdorferi [26]. TLR2 and 5 were expressed
on the cell surface and/or in endosomal compartments in
a manner that correlated with the internalization of
B. burgdorferi by microglia, which is consistent with
other studies that showed a role for both TLR tran-
scripts and phagocytosis in the immune response to
B. burgdorferi [35,36]. Those results indicated that
these receptors might be involved in the innate im-
mune response towards B. burgdorferi and also that
these pathways could play a role in neuronal apop-
tosis mediated by microglial inflammation [23]. The
current study was undertaken to further delineate the
role of these and other receptors and pathways in mediat-
ing microglial inflammation in response to B. burgdorferi,
using RNAi technology and other methods. Our results
show that TLR2 and TLR5 are both involved in the pro-
duction of cytokines and chemokines from primary micro-
glia, with TLR2 probably being the predominant TLR
(based on the number of mediators that were suppressed
by siRNA and inhibitor, from those that were assayed,
Figures 1, 2, and 3). This result is in accordance with
the presence of TLR2 and TLR5 ligands, namely, lipo-
proteins and flagellin, respectively, which are present
in large amounts in B. burgdorferi. The outcome of our
TLR experiments is in partial contrast with the results
of Dennis et al. [25] with THP1 monocytes, wherein
TLR2 had a role in mediating inflammation in response to
B. burgdorferi, but not TLR5. The role of microglial TLR4 in
B. burgdorferi-mediated inflammation is more ambiguous.
Figure 3 Role of TLR5 in immune mediator production from NHP microglia in response to B. burgdorferi. A concentration of 25 nM TLR5
or CTL siRNA was used to determine the role of microglial TLR5 receptor in mediating inflammatory responses to B. burgdorferi. A pattern of
inhibition was determined from four experiments performed with microglia obtained from two animals. A representative pattern is shown, with
bars portraying standard deviation. FliC was used as a positive control for siRNA efficacy, and the medium alone was used as a control for basal
expression of inflammatory mediators. *P < 0.05; **P < 0.01; ***P < 0.001. The inset figure shows magnification of the data within the square at the
bottom. CCL2, chemokine (C-C) motif ligand 2; CTL, control; CXCL8, chemokine (C-X-C) motif ligand 8; IL-6, interleukin 6; siRNA, small interfering
RNA; TLR, Toll-like receptor; TNF, tumor necrosis factor.
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but may contain a lipooligosaccharide (LOS) moiety [37]. In
our previous study [26], this receptor was also upregulated
by B. burgdorferi concomitantly with TLR2 and 5, perhaps
as a result of coordinated regulation without ligand involve-
ment, or through the LOS. In our current study, we found
that a specific inhibitor of TLR4 intracellular signaling
showed a trend towards increased production of IL-6,
CXCL8, and CCL2 in the presence of B. burgdorferi
(Table 1). This indicated that TLR4 might trigger an inhibi-
tory pathway during exposure to B. burgdorferi, coordinately
regulated to control excessive cytokine/chemokine produc-
tion. The effect of TLR4 siRNA, on the other hand, was the
opposite. The knock-down of TLR4 suppressed CXCL8 pro-
duction in microglia and generally showed an opposite effect
from that seen with CLI-095 (Table 1). However, both the
inhibitor and TLR4 siRNA showed the exact same trend in
suppressing IL-6, CXCL8, and TNF production with the
classic TLR4 ligand LPS. It is possible that, in the absence of
a classic LPS like moiety and therefore a true agonist, theinhibition of TLR4 may have pleiotropic effects. Further
experimentation is required for delineation of TLR4 in
B. burgdorferi-mediated inflammation, which currently
remains inconclusive.
Both TLR2 and TLR5 have been shown to signal through
the adaptor molecule MyD88 [38,39], and in accordance
with these other studies, suppression of MyD88 siRNA did
inhibit the production of all four inflammatory mediators
tested, in the presence of the bacterium (Figure 4).
However, the suppression was not to medium-alone
levels, indicating the possibility that the siRNA was in-
sufficient. A higher concentration of siRNA (≥50 nM)
was also tested, but due to varying toxicity of the tran-
scription complexes on microglia from different animals,
these data have not been presented here. However, as pri-
mary cells are hard to transfect, the incomplete blockade
of cytokines and chemokines seen in our study is more
likely a result of low-transfection efficiencies observed in
these cells [40]. Additionally, it is possible that signal
transduction is conducted through other molecules such
Figure 4 Intracellular signaling through MyD88. siRNA for MyD88 (25 nM) was used to determine the role of this adaptor molecule in
mediating signaling events in microglia in the presence of B. burgdorferi. Data are representative of cytokine/ chemokine pattern as determined
from three independent experiments. Bars represent standard deviation. *P < 0.05; **P < 0.01; ***P < 0.001. Pam3CSK4 was used as a positive
control for MyD88-mediated effects, and the medium as a control for baseline expression. CCL2, chemokine (C-C) motif ligand 2; CTL, control;
CXCL8, chemokine (C-X-C) motif ligand 8; IL-6, interleukin 6; MyD88, myeloid differentiation primary response 88; siRNA, small interfering RNA;
TNF, tumor necrosis factor.
Parthasarathy and Philipp Journal of Neuroinflammation  (2015) 12:60 Page 9 of 14as Toll/interleukin-1 receptor (TIR)-domain-containing
adapter-inducing interferon-β (TRIF). Although only
few studies exist on the possibility of TLR2- or TLR5-
mediated signaling through TRIF [41,42], it is never-
theless a viable alternative in microglia.
NOD2 is an intracellular receptor that signals upon bind-
ing of MDP. Studies conducted to date with B. burgdorferi
have largely shown that this spirochete induces inflamma-
tion through this receptor [29-32]. In our study, however,
suppression of NOD2 expression with siRNA (verified in
Figure 6) showed that, in the presence of B. burgdorferi, this
resulted in an increase in the production of inflammatory
mediators, with the exception of CXCL8 (Figure 5 and
Table 2). This partial pattern of upregulation in the pres-
ence of NOD2 siRNA was seen in microglia at both the
concentrations tested and was also evident with the positive
control MDP. At least part of this result with NOD2 siRNA
was also obtained with Gefitinib, an inhibitor of RIP2,
a kinase that functions downstream of NOD2. Addition of
Gefitinib and B. burgdorferi also upregulated CCL2production on average, from four experiments in micro-
glia from two animals (data not shown). In addition,
Gefitinib significantly increased the production of MIP-1β
in the presence of B. burgdorferi, and a similar trend was
observed with MIP1α and RANTES production in two
experiments (not shown). Although Gefitinib also sup-
presses EGFR signaling, taking all the data together, it
is likely that NOD2 signaling (perhaps together with
EGFR) suppresses production of at least a few chemo-
kines and/or cytokines, perhaps to control inflamma-
tion mediated through TLRs. In fact, NOD2 has been
shown to inhibit TLR2-mediated signaling in other
studies [43,44], indicating that this possibility is viable.
In one study, when splenocytes from NOD2-deficient
mice were stimulated with peptidoglycan (PGN), a
TLR2 ligand, the cytokine production was found to be
higher than those from wild-type mice [44]. Similarly,
when mouse peritoneal macrophages were stimulated
with both PGN and MDP, production of IL-1β was sig-
nificantly lower than when stimulated with PGN alone
Figure 5 Role of NOD2 receptor in mediating inflammatory molecule release from microglia exposed to B. burgdorferi. Primary microglia
were co-incubated with 15 nM NOD2 or CTL siRNA for 24 h, followed by B. burgdorferi infection for an additional 24 h. Supernatants were col-
lected 24 h post infection and analyzed for chemokine and cytokine expression. A representative pattern from five independent experiments from
four animals is shown. Bars represent standard deviation. NOD2 ligand MDP was used as a positive control for NOD2 mediated effects. *P < 0.05;
**P < 0.01; ***P < 0.001. CCL2, chemokine (C-C) motif ligand 2; CTL, control; CXCL8, chemokine (C-X-C) motif ligand 8; IL-6, interleukin 6; MDP, mur-
amyl dipeptide; NOD2, nucleotide-binding oligomerization domain containing 2; siRNA, small interfering RNA; TNF, tumor necrosis factor.
Table 2 Average fold changea in chemokine/cytokine
expression in the presence of 25 to 30 nM NOD2 siRNA
Cytokine or chemokine/
treatment
IL-6 CXCL8 CCL2 TNF
B. burgdorferi 0.817b 1.165c 0.803b 0.703b
(±0.041) (±0.117) (±0.118) (±0.116)
MDP 0.7034b 1.0295 0.6889b 0.6486b
(±0.170) (±0.115) (±0.062) (±0.494)
aFold changes in chemokine/cytokine expression were calculated as treatment
with control siRNA/treatment with NOD2 siRNA. Values for B. burgdorferi
(MOI 10:1) treatment were calculated from three experiments using
microglia from three different animals; MDP (2.5 μg/mL) was from four
experiments from four animals. Values higher than 1.0 represent fold-down
regulation of chemokine/cytokine while values less than 1.0 represent an increase.
Standard error of the mean (SEM) is indicated within parentheses. bA statistically
significant increase in expression. cValues that were significantly downregulated in
the majority of experiments (≥67%). chemokine (C-C) motif ligand 2; CXCL8,
chemokine (C-X-C) motif ligand 8; IL-6, interleukin 6; MDP, muramyl
dipeptide; TNF, tumor necrosis factor.
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way, downregulating TLR2-mediated responses. Also,
our results are somewhat similar to those obtained by
Chauhan et al. [45] where, in the absence of NOD2,
osteoblasts that passively internalized Staphylococcus
aureus or a non-invasive strain of Salmonella produced
elevated levels of select cytokines, but not with actively in-
vasive Salmonella. Additionally, NOD2-mediated effects
might also be dose dependent, as seen in the study by
Borm et al. [46] where MDP added in low doses to TLR2-
primed monocytes augmented cytokine responses while it
inhibited them at a higher dose. This indicates that host
and type of cell, dose effects, bacterial species, and inva-
sive potential of bacteria and other factors may all play a
role in differential NOD2-mediated effects.
MDP is generally known to be a specific ligand for
NOD2. However, in our study, in the presence of
NOD2 siRNA, levels of most chemokines/cytokines
went up significantly, indicating that the basal levels
Figure 6 Efficacy of NOD2 siRNA in suppressing NOD2 protein expression. RNAi experiment was carried out according to the protocols
described in the ‘Methods’ section, with 25 nM control or NOD2 siRNA and 2.5 μg/mL of MDP. Following fixation in paraformaldehyde, cells were
analyzed for NOD2 expression by immunofluorescence. (A) shows cells (assigned red) stained for NOD2 (green fluorescence) with bars
representing 25 μm, and (B) shows the percent change in NOD2 expression in the two treatment groups, with vertical bars representing
standard deviation. Data was collected from two experiments conducted on microglia collected from a single animal.*P < 0.05. CTL, control; MDP,
muramyl dipeptide; NOD2, nucleotide-binding oligomerization domain containing 2; siRNA, small interfering RNA.
Table 3 Average fold changea in chemokine/cytokine
expression in the presence of various MAPK pathway
inhibitors
Cytokine/treatment (2.5 μM) IL-6 CXCL8 CCL2 TNF
MEK1/2 2.639 2.215 3.813 31.546
(±0.445) (±0.226) (±1.138) (±18.767)
JNK 1.475 1.760 1.512 3.991
(±0.219) (±0.202) (±0.083) (±0.508)
P38 1.382 1.397 1.153 6.301
(±0.065) (±0.057) (±0.142) (±2.338)
aFold change values were calculated as B. burgdorferi with solvent alone/B.
burgdorferi with inhibitor from four experiments for each treatment with
microglia from two to three animals. Values higher than 1.0 represent fold-down
regulation of chemokine/cytokine while values less than 1.0 represent an increase.
Standard error of the mean (SEM) is indicated within parentheses. Values that were
significantly downregulated in all of the experiments are indicated in italics. CCL2,
chemokine (C-C) motif ligand 2; CXCL8, chemokine (C-X-C) motif ligand 8; IL-6,
interleukin 6; JNK, Jun N-terminal kinase; MEK, MAP kinase kinase; TNF, tumor
necrosis factor.
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as well [47]. The MDP used in our system is a synthetic
form, according to the manufacturer. Therefore, the likeli-
hood of endotoxin or peptidoglycan contamination is very
low. But, monoacylated forms of MDP have been shown
to trigger TLR2/4 pathways [48]. Whether MDP deriv-
atives are formed in cell culture in the presence of
eukaryotic cells like microglia, is not known but is an
as yet unproven possibility.
The majority of the studies conducted thus far have
implicated downstream MAPK pathways in mediating
inflammation in a wide variety of cells in response to
TLR triggers [33,34,49]. The analysis we performed in
NHP primary microglia with the aid of specific inhibi-
tors showed that, of the three MAPK pathways, the ERK
pathway predominates in mediating inflammation, followed
by the JNK and p38 pathways (Table 3). This order of rele-
vance is similar to that observed in MAPK pathways of hu-
man oligodendrocytes in response to B. burgdorferi [24].
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been shown to be very high for its target [50], we did not
use additional inhibitors. However, we did use additional
inhibitors for p38 and JNK pathways to reconfirm the pat-
tern of inhibition with these specific MAPK pathways and
found them unchanged.
We have conducted a comprehensive analysis of the role
of receptors and pathways in mediating inflammation in
primary NHP microglia in response to B. burgdorferi.
While we have attempted to provide more than one lineFigure 7 Proposed model of signaling pathways activated in primary
the bacterium, the microglial TLR2 and TLR5, respectively, sense B. burgdorf
phagocytosed bacteria), initiating downstream responses by recruitment of
at the surface and in the intracellular compartments or exclusively through
internalization. However, once signaling is initiated, further downstream sig
leading to production of inflammatory mediators. Upregulation of TLR4 ha
lipooligosaccharide moiety or as a result of concomitant activation along w
intracellular localization (hence the question mark in the corresponding arr
molecules in phagocytosed bacteria, leads to anti-inflammatory effects, esp
outcome in microglia in response to B. burgdorferi is likely through the positive a
downstream signaling lines depicts signal strength. Arrowheads indicate inductio
show additional possible inhibitory signals. Dotted lines indicate internalization
endosome in open ovals. Dashed and dotted lines indicate unclear processes
motif ligand 8; ERK, extracellular signal-regulated kinase; IL-6, interleukin
myeloid differentiation primary response 88; NOD2, nucleotide-binding
tumor necrosis factor; TRIF, Toll/interleukin-1 receptor (TIR)-domain-contof evidence in each case, this was not always possible, ei-
ther due to lack of availability of certain reagents or their
associated toxicity or lack of specificity towards a particu-
lar target molecule. However, we do provide sufficient evi-
dence for a picture to emerge on the role of these various
receptors and pathways in the response to B. burgdorferi
and have depicted this in the model shown in Figure 7.
We show here that multiple receptors and pathways posi-
tively and negatively regulate inflammation in primary
microglia. A study of the roles of these inflammatoryNHP microglia in response to B. burgdorferi. Upon contact with
eri lipoproteins and flagella (likely exposed by fragmented or by
adaptor molecules such as MyD88. Whether signaling is initiated both
the latter is not clear, neither is the mechanism of TLR2/5
naling leads to activation of MAPK pathways, mainly the ERK pathway,
s been detected by confocal microscopy, perhaps through a
ith other TLRs. Its role in inflammation is unclear and neither is its
ow). Signaling through intracellular NOD2, mediated by MDP
ecially for CCL2 and perhaps other mediators. Thus, the overall inflammatory
nd negative regulation of several key signaling pathways. Thickness of the
n, and horizontal bars at the end of the lines indicate inhibition. Dashed lines
either through phagocytosis or endocytosis, with phagosome and/or
. CCL2, chemokine (C-C) motif ligand 2; CXCL8, chemokine (C-X-C)
6; JNK, Jun N-terminal kinase; MDP, muramyl dipeptide; MyD88,
oligomerization domain containing 2; TLR, Toll-like receptor; TNF,
aining adapter-inducing interferon-β.
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underway.
Conclusions
The overall immune response from primary NHP micro-
glia upon exposure to B. burgdorferi results from a com-
plex network of multiple receptors and pathways that
are triggered by a variety of ligands on the bacterium.
The result is a tightly regulated immune network with
both positive and negative regulation of immune media-
tors. The key receptors and pathways that were identified
in this study may serve as targets for new therapeutics in
CNS Lyme disease.
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